Exchange Traded Concepts LLC Purchases 89,508 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Exchange Traded Concepts LLC increased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 36.4% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 335,325 shares of the biopharmaceutical company’s stock after purchasing an additional 89,508 shares during the quarter. Gilead Sciences makes up about 0.6% of Exchange Traded Concepts LLC’s investment portfolio, making the stock its 23rd largest holding. Exchange Traded Concepts LLC’s holdings in Gilead Sciences were worth $30,974,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in GILD. FMR LLC increased its holdings in shares of Gilead Sciences by 79.4% in the 3rd quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company’s stock worth $2,780,329,000 after purchasing an additional 14,680,161 shares in the last quarter. Wellington Management Group LLP raised its position in Gilead Sciences by 50.9% in the 3rd quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company’s stock worth $2,900,921,000 after buying an additional 11,665,593 shares during the last quarter. Point72 Asset Management L.P. lifted its stake in Gilead Sciences by 350.1% during the 3rd quarter. Point72 Asset Management L.P. now owns 2,305,270 shares of the biopharmaceutical company’s stock valued at $193,274,000 after acquiring an additional 1,793,145 shares during the period. International Assets Investment Management LLC boosted its holdings in shares of Gilead Sciences by 8,238.4% during the 3rd quarter. International Assets Investment Management LLC now owns 1,642,504 shares of the biopharmaceutical company’s stock valued at $137,708,000 after acquiring an additional 1,622,806 shares during the last quarter. Finally, Deerfield Management Company L.P. Series C bought a new stake in shares of Gilead Sciences in the second quarter worth approximately $102,298,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on GILD shares. Sanford C. Bernstein assumed coverage on shares of Gilead Sciences in a report on Thursday, October 17th. They issued an “outperform” rating and a $105.00 target price on the stock. Cantor Fitzgerald reiterated a “neutral” rating and set a $80.00 price objective on shares of Gilead Sciences in a research note on Wednesday, December 11th. Bank of America reissued a “buy” rating and set a $109.00 price target on shares of Gilead Sciences in a report on Tuesday, December 10th. UBS Group raised their target price on shares of Gilead Sciences from $70.00 to $96.00 and gave the company a “neutral” rating in a research note on Thursday, November 21st. Finally, Wolfe Research initiated coverage on shares of Gilead Sciences in a report on Friday, November 15th. They issued an “outperform” rating and a $110.00 target price for the company. Eleven equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have assigned a strong buy rating to the company. According to data from MarketBeat, Gilead Sciences presently has an average rating of “Moderate Buy” and an average target price of $97.96.

Gilead Sciences Trading Down 0.2 %

NASDAQ:GILD opened at $92.78 on Friday. The stock’s 50-day moving average is $91.63 and its two-hundred day moving average is $84.63. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $98.90. The stock has a market cap of $115.63 billion, a PE ratio of 1,030.87, a price-to-earnings-growth ratio of 1.31 and a beta of 0.18. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, beating the consensus estimate of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The company had revenue of $7.55 billion for the quarter, compared to the consensus estimate of $7.01 billion. During the same quarter last year, the company posted $2.29 earnings per share. The company’s revenue for the quarter was up 7.0% compared to the same quarter last year. As a group, equities research analysts forecast that Gilead Sciences, Inc. will post 4.36 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, December 30th. Shareholders of record on Friday, December 13th were issued a dividend of $0.77 per share. The ex-dividend date of this dividend was Friday, December 13th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.32%. Gilead Sciences’s payout ratio is presently 3,422.22%.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, Director Jeffrey Bluestone sold 6,788 shares of Gilead Sciences stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total transaction of $620,355.32. Following the completion of the transaction, the director now directly owns 8,920 shares of the company’s stock, valued at $815,198.80. The trade was a 43.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Merdad Parsey sold 25,590 shares of the company’s stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the completion of the transaction, the insider now owns 99,599 shares in the company, valued at $9,113,308.50. This trade represents a 20.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 456,234 shares of company stock valued at $42,130,461 in the last three months. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.